ID/IDA in Heart Failure
Overview
This lecture by Dr. Hadi Skouri explores the impact of iron deficiency in heart failure and its association with reduced functional capacity and adverse outcomes. It reviews recent evidence and updated guidelines supporting the role of high-dose IV iron therapy in improving symptoms, exercise tolerance, and quality of life among HF patients.
Prof. Hadi Skouri, Professor of Clinical Medicine-Cardiology at Balamand University School of Medicine. Consultant of Advanced heart failure and Cardio-oncology at Sheikh Shakbout Medical City, Abu Dhabi-UAE. He is serving as the Director of the Heart Failure service and initiated the first UAE cardio-oncology service
What is the approximate prevalence of iron deficiency in patients with chronic heart failure?
- 10%
- 25%
- Up to 55%
- 90%
Which diagnostic criteria define iron deficiency in heart failure?
- Ferritin <50 µg/L or TSAT <30%
- Ferritin <100 µg/L, or ferritin 100–300 µg/L with TSAT <20%
- Ferritin >300 µg/L regardless of TSAT
- TSAT >25% and ferritin >100 µg/L
The CONFIRM-HF trial showed that ferric carboxymaltose significantly improved which functional outcome?
- Blood pressure
- 6-minute walk distance
- Left ventricular ejection fraction
- BNP levels only
In AFFIRM-AHF, ferric carboxymaltose compared to placebo had what impact on outcomes in patients stabilized after an episode of acute HF?
- Reduced all-cause mortality
- Reduced HF hospitalizations but no significant mortality benefit
- Increased risk of arrhythmias
- No difference in hospitalizations or mortality
What is a recognized limitation of oral iron supplementation in heart failure patients with iron deficiency?
- Poor GI absorption and lack of demonstrated clinical benefit in RCTs
- High cost compared to IV therapy
- Increased risk of hyperkalemia
- Reduced renal clearance
The CME certification is provided for live webinar attendance only.
GCC-FCM-2500035 I Date of preparation: October 2025